Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model

Repeated scanning ultrasound in the absence of a therapeutic agent removes amyloid-β and restores memory in an Alzheimer’s disease mouse model. Can ultrasound restore memory? Transgenic mice with increased amyloid-β (Aβ) production show several aspects of Alzheimer’s disease, including Aβ deposition and memory impairment. By repeatedly treating these Aβ-forming mice with scanning ultrasound, Leinenga and Götz now demonstrate that Aβ is removed and memory is restored as revealed by improvement in three memory tasks. These improvements were achieved without the use of any therapeutic agent, and the scanning ultrasound treatment did not induce any apparent damage to the mouse brain. The authors then showed that scanning ultrasound activated resident microglial cells that took up Aβ into their lysosomes. These findings suggest that repeated scanning ultrasound may be a noninvasive method with potential for treating Alzheimer’s disease. Amyloid-β (Aβ) peptide has been implicated in the pathogenesis of Alzheimer’s disease (AD). We present a nonpharmacological approach for removing Aβ and restoring memory function in a mouse model of AD in which Aβ is deposited in the brain. We used repeated scanning ultrasound (SUS) treatments of the mouse brain to remove Aβ, without the need for any additional therapeutic agent such as anti-Aβ antibody. Spinning disk confocal microscopy and high-resolution three-dimensional reconstruction revealed extensive internalization of Aβ into the lysosomes of activated microglia in mouse brains subjected to SUS, with no concomitant increase observed in the number of microglia. Plaque burden was reduced in SUS-treated AD mice compared to sham-treated animals, and cleared plaques were observed in 75% of SUS-treated mice. Treated AD mice also displayed improved performance on three memory tasks: the Y-maze, the novel object recognition test, and the active place avoidance task. Our findings suggest that repeated SUS is useful for removing Aβ in the mouse brain without causing overt damage, and should be explored further as a noninvasive method with therapeutic potential in AD.

[1]  A. Mahipal Clinical trials and drug development. , 2014, Cancer control : journal of the Moffitt Cancer Center.

[2]  K. Hynynen,et al.  Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound. , 2012, Human gene therapy.

[3]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[4]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[5]  E. Masliah,et al.  Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.

[6]  Tony Wyss-Coray,et al.  Immune Activation in Brain Aging and Neurodegeneration: Too Much or Too Little? , 2009, Neuron.

[7]  G. Melacini,et al.  In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin. , 2013, Journal of Alzheimer's disease : JAD.

[8]  Matthew E. Downs,et al.  Transcranial cavitation detection in primates during blood-brain barrier opening-a performance assessment study , 2014, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control.

[9]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[10]  J. Cirrito,et al.  Genetic Modulation of Soluble Aβ Rescues Cognitive and Synaptic Impairment in a Mouse Model of Alzheimer's Disease , 2014, The Journal of Neuroscience.

[11]  Elisa E Konofagou,et al.  Noninvasive and localized neuronal delivery using short ultrasonic pulses and microbubbles , 2011, Proceedings of the National Academy of Sciences.

[12]  K. Hynynen,et al.  MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study , 2013, The Lancet Neurology.

[13]  J. Jorquera,et al.  Therapeutic albumin binding to remove amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.

[14]  M. Hennerici,et al.  Clearance of albumin following ultrasound-induced blood–brain barrier opening is mediated by glial but not neuronal cells , 2011, Brain Research.

[15]  D. Holtzman,et al.  Active and passive immunotherapy for neurodegenerative disorders. , 2008, Annual review of neuroscience.

[16]  Joel Alemibola Elegbe The Need for a Paradigm Shift , 2016, WATER AND SOCIETY.

[17]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[18]  Rajiv Chopra,et al.  Antibodies Targeted to the Brain with Image-Guided Focused Ultrasound Reduces Amyloid-β Plaque Load in the TgCRND8 Mouse Model of Alzheimer's Disease , 2010, PloS one.

[19]  E. Masliah,et al.  Can Alzheimer disease be prevented by amyloid-β immunotherapy? , 2010, Nature Reviews Neurology.

[20]  J. Filosa,et al.  A quantitative spatiotemporal analysis of microglia morphology during ischemic stroke and reperfusion , 2013, Journal of Neuroinflammation.

[21]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[22]  B. Liu,et al.  Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study , 2012, Neurodegenerative Diseases.

[23]  D. Selkoe,et al.  Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide , 2007, Nature Reviews Molecular Cell Biology.

[24]  Ralf Seip,et al.  Targeted Ultrasound-Mediated Delivery of Nanoparticles: On the Development of a New HIFU-Based Therapy and Imaging Device , 2010, IEEE Transactions on Biomedical Engineering.

[25]  Ezzie Hutchinson,et al.  Systems neuroscience: The stress of dieting , 2011, Nature Reviews Neuroscience.

[26]  B. Winblad,et al.  Alzheimer's disease: clinical trials and drug development , 2010, The Lancet Neurology.

[27]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[28]  Natalia Vykhodtseva,et al.  Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. , 2012, Cancer research.

[29]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[30]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[31]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[32]  F. LaFerla,et al.  Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice , 2013, Journal of neurochemistry.

[33]  Paul A Dayton,et al.  Direct observations of ultrasound microbubble contrast agent interaction with the microvessel wall. , 2007, The Journal of the Acoustical Society of America.

[34]  S. Fowler,et al.  Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β , 2013, Brain : a journal of neurology.

[35]  K. Hynynen,et al.  Multiphoton Imaging of Ultrasound/Optison Mediated Cerebrovascular Effects in vivo , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[36]  Elisa E. Konofagou,et al.  Optimization of the Ultrasound-Induced Blood-Brain Barrier Opening , 2012, Theranostics.

[37]  T. Golde,et al.  Robust Amyloid Clearance in a Mouse Model of Alzheimer's Disease Provides Novel Insights into the Mechanism of Amyloid-β Immunotherapy , 2011, The Journal of Neuroscience.

[38]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[39]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Manabu Kinoshita,et al.  Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Kullervo Hynynen,et al.  Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound , 2013, Experimental Neurology.

[42]  Elisa E Konofagou,et al.  Noninvasive and Transient Blood-Brain Barrier Opening in the Hippocampus of Alzheimer's Double Transgenic Mice Using Focused Ultrasound , 2008, Ultrasonic imaging.